/GENF.L

GENF.L Stock - Genflow Biosciences plc

Q: What is the analyst price target for GENF.L?

Analyst price target information is not currently available for GENF.L.

Q: What is GENF.L's market cap?

Market capitalization information is not currently available for GENF.L.

Healthcare|Biotechnology|LSE

$1.80-5.26%

$0.10 (-5.26%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.98

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GENF.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.31

52W High$2.70

52W Low$0.55

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-1,204	$-1,034	$-130	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-1,266,764	$-1,798,560	$-1,334,943	$-988,096	$-649,920
Net Income	$-1,587,235	$-1,628,705	$-1,335,326	$-988,294	$-651,006
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.00	$-0.01	$-0.00	$-0.00	$-0.82

Company Overview

Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.

Visit Website

Earnings History & Surprises

GENF.L

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.00

Q4 2023

EPS Surprise History

Q1 22

No data

Q2 22

No data

Q3 22

No data

Q4 22

No data

Q1 23

No data

Q2 23

No data

Q3 23

No data

Q4 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2025	May 1, 2025	—	—	—	—
Q2 2024	May 7, 2024	—	—	—	—
Q4 2023	Dec 31, 2023	—	$-0.00	—	—
Q3 2023	Sep 29, 2023	—	$-0.00	—	—
Q2 2023	Jun 30, 2023	—	$-0.00	—	—
Q1 2023	Mar 31, 2023	—	$-0.00	—	—
Q4 2022	Dec 31, 2022	—	$-0.00	—	—
Q3 2022	Sep 30, 2022	—	$-0.00	—	—
Q2 2022	Jun 30, 2022	—	$-0.00	—	—
Q1 2022	Mar 31, 2022	—	$-0.00	—	—
Q2 2021	Jun 30, 2021	—	$-0.00	—	—
Q1 2021	Mar 31, 2021	—	$-0.00	—	—